(as of December 2012)
The company was incorporated as a privately held corporation in Dec 2006. Since its start, the company has been steadily growling and is now ranked among the top national companies in the country.
The company is managed by people with very solid background in the pharmaceutical market. Xeno has a full complement of Territory Managers and District Managers with full nation-wide promotions coverage. The team is fully trained for ethical promotions to healthcare professionals.
Xeno has full-service capabilities, including Regulatory Affairs for product registration, Product Management and HR Training & Development. Our Finance system is equipped with SAP (system application and products) for accounting and internal control.
We are a pharmaceutical company with a heart for the patient; a trusted partner of the medical profession in providing world class healthcare through products and services that offer best value for money.
Xeno Pharmaceuticals Phils. Inc. is a company with a strong capability to build brands. It seeks to
engage in a wide range of strategic partnerships with other companies to build a portfolio of products that offer value for money to doctors and their patients.
The initial members of the board and officers:
Amado T Tadena Founding Chairman
Noel R Isberto Vice Chairman
Sabina Vina H Tadena Treasurer
Ana Marie T Pichay Corporate Secretary
Noel A Laman Legal Counsel
Josefina U De Vera Managing Director, XENO
Anna Pichay General Manager, POGI
Ephraim C Cruzado Finance Director
Liza V Alivia Human Resources Director
Cris J Palafox Regulatory Affairs Director
Xeno Pharmaceuticals Phils. Inc. & Pedia OGCare Inc. offer quality products at affordable prices for best value for money to the vast majority of the population.
With product quality as a prime factor, Xeno has carefully selected its partners by ensuring that all its products are produced at US FDA or UK MHRA accredited facilities.
Xeno has steadily increased its product offerings from an initial 5 brands in 2007 to over 20 brands in 2010. In the last 2 years, patented and differentiated products have been launched, thereby solidifying Xeno’s ability to do brand building.
In the branded generics category, Xeno has built its brands to rank in the top 3 to 5 of every Therapeutic Category it competes in.
Xeno will continue to pursue brand building and new product launches to further broaden its portfolio.